Sweetch Health App for Chronic Disease Management

The Problem

Almost 50% of adults living in developed countries have chronic disease. The World Health Organization indicates that only about 50% of patients with chronic diseases follow treatment recommendations, and only about 20% follow disease prevention recommendations.
Chronic diseases account for 86% of all healthcare spending. Raising adherence to disease prevention and disease management recommendations has greater impact on public health than any improvement in specific medical care.

Sweetch's Solution - a unique personalised experience that can be scaled

In a mobile-first world, people are always connected – but not always available and attentive. Sweetch is a clinically validated Patient Engagement Platform that utilises Artificial Intelligence (AI) to significantly increase patients’ adherence to essential health promotion, disease prevention and disease management recommendations in a highly personalised and scalable way. Sweetch is HIPAA, GDPR and Australian Privacy Act compliant.

Deep Tech – Combining Advanced Data Science with Behavioural Modification

Designed to work in real life, Sweetch’s AI-powered Behavioural Intelligence Engine converts millions of data points originating from a patient's smart phone and other connected devices into contextual, hyper-personalised, just-in-time, just-in-place, recommendations. Through analysing the patient’s current context, past behaviours and real-world capabilities, Sweetch’s proprietary algorithms identify the individual’s compliance patterns and continuously optimise the recommendations that each patient receives. Sweetch’s Just-in-Time Adaptive Intervention approach leads to significantly improved engagement and ultimately improved health outcomes.

Clinical Outcomes

In a clinical trial conducted by Johns Hopkins, Sweetch achieved 86% patient retention and clinically significant effects on weight loss, physical activity increase, and Hemoglobin A1C reduction. Based on these outstanding results, the Hopkins researchers are now commencing a large NIH-funded randomised controlled study.

https://www.jmir.org/2018/2/e72/

One Dynamic Platform for Multiple Chronic Conditions

As an AI-powered solution, Sweetch enables seamless customisation to different disease domains. Sweetch is currently being deployed in four verticals:

1. Cardiovascular and Metabolic Areas – Diabetes, Pre-diabetes, Obesity, Coronary Artery Disease, and Atrial Fibrillation;
2. Oncology – Breast Cancer and Prostate Cancer;
3. Autoimmune Diseases – Rheumatoid Arthritis and IBD; and
4. Population Health.

Differentiation

1. Deep tech – developed by a leading team of data scientists over the last 5 years, Sweetch is the first mobile health platform to combine predictive analytics and behavioural modification (provisional patent application P-79151-USP3).
2. Scalability – fully automated patient engagement platform uniquely positioned for global scaling.
3. Flexibility – seamless customisation to different disease domains and corporate partners.
4. High cost-efficiency – outcome-based business model.
5. Unique Data Asset – by integrating patients’ behavioural data, patients reported outcomes, biometric measures, treatment adherence patterns, and clinical outcomes, Sweetch creates a unique data asset that doesn’t exist today with significant implications on chronic disease prevention and management.

Global Traction

Sweetch’s business partners include Insurers, Pharma Companies, Healthcare Providers, Self-insured Employers and Patient Support Programs spanning across the US, the EU, and APAC. These include, among others –

• Siemens Healthineers;
• WellSpan Health – one of the largest integrated health care systems in Pennsylvania - https://www.prnewswire.com/news-releases/ai-mobile-health-app-sweetch-partners-with-wellspan-health-to-help-fight-diabetes-300741126.html
• Leading global pharma companies – Roche, Sanofi, Janssen, and Novo Nordisk;
• The Baker Institute – Australia’s leading Heart & Diabetes Clinical and ResearchInstitute;
• The National Association of Chronic Disease Directors;
• Icon Group – one of the largest cancer care networks in APAC;
• EMIS – UK’s most popular clinical system (referenced as React2D) - https://www.mobihealthnews.com/content/europe/iqvia-emis-health-partner-support-gps-england-electronically-prescribe-apps-patients